NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.…
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NeuroPace (NASDAQ: NPCE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 216 employees.
The shares were at 7.950 USD on 20 November 2026, down 39.4% over 52 weeks. Its 52-week range is 5.470 USD to 19.60 USD: the price is 59.4% below the high and 45.3% above the low.
Its market capitalisation is 273.89M USD.
NeuroPace reports return on equity of -112.8%, an operating margin of -9.5% and revenue down 1.1% year over year.
Its debt exceeds its cash by 20.31M USD, a debt-to-equity ratio of 3.72. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 12.33 USD is 55.1% above the current price. The next earnings report is expected on 2 March 2027.